T lymphocytes impair P-glycoprotein function during neuroinflammation

Journal of Autoimmunity

Volumn 34, Issue 4, 2010, Pages 416-425

  Kooij, Gijs ^a   van Horssen, Jack ^a   de Lange, Elizabeth C M ^b   Reijerkerk, Arie ^a   van der Pol, Susanne M A ^a   van het Hof, Bert ^a   Drexhage, Joost ^a   Vennegoor, Anke ^a   Killestein, Joep ^a   Scheffer, George ^a   Oerlemans, Ruud ^a   Scheper, Rik ^a   van der Valk, Paul ^a   Dijkstra, Christine D ^a   de Vries, Helga E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Blood brain barrier; Experimental allergic encephalomyelitis; Multiple sclerosis; Nuclear factor kappa B; P Glycoprotein; T cells

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BRAIN; BRAIN CHEMISTRY; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEUROIMMUNOMODULATION; P-GLYCOPROTEIN; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 77952240450     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.10.006     Document Type: Article

References (41)

1. Vos C.M., Geurts J.J., Montagne L., van Haastert E.S., Bo L., van der Valk P., et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005, 20:953-960.
2. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
3. Kirk J., Plumb J., Mirakhur M., McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003, 201:319-327.
4. Plumb J., McQuaid S., Mirakhur M., Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002, 12:154-169.
5. Reijerkerk A., Kooij G., van der Pol S.M., Khazen S., Dijkstra C.D., de Vries H.E. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006, 20:2550-2552.
6. Schreibelt G., Kooij G., Reijerkerk A., van D.R., Gringhuis S.I., van der P.S., et al. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 2007.
7. van Horssen J., Bo L., Vos C.M., Virtanen I., de Vries H.E. Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol 2005, 64:722-729.
8. Bauer B., Hartz A.M., Fricker G., Miller D.S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood.) 2005, 230:118-127.
9. Loscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2:86-98.
10. Drach J., Gsur A., Hamilton G., Zhao S., Angerler J., Fiegl M., et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996, 88:1747-1754.
11. Ernest S., Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol 1999, 10:2306-2313.
12. Frank M.H., Denton M.D., Alexander S.I., Khoury S.J., Sayegh M.H., Briscoe D.M. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001, 166:2451-2459.
13. Meijer O.C., de Lange E.C., Breimer D.D., de Boer A.G., Workel J.O., de Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998, 139:1789-1793.
14. Schinkel A.H., Smit J.J., van T.O., Beijnen J.H., Wagenaar E., van D.L., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
15. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
16. Langford D., Grigorian A., Hurford R., Adame A., Ellis R.J., Hansen L., et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004, 63:1038-1047.
17. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005, 6:591-602.
18. Yu C., Argyropoulos G., Zhang Y., Kastin A.J., Hsuchou H., Pan W. Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia. Cell Physiol Biochem 2008, 22:745-756.
19. Bauer B., Hartz A.M., Miller D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007, 71:667-675.
20. Floris S., Blezer E.L., Schreibelt G., Dopp E., van der Pol S.M., Schadee-Eestermans I.L., et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004, 127:616-627.
21. de Lange E.C., de B.G., Schinkel A.H., de Boer A.G., Breimer D.D. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 1998, 15:1657-1665.
22. Weksler B.B., Subileau E.A., Perriere N., Charneau P., Holloway K., Leveque M., et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005, 19:1872-1874.
23. Nabatov A.A., van M.T., Geijtenbeek T.B., Pollakis G., Paxton W.A. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression. FEBS J 2006, 273:4944-4958.
24. Perriere N., Demeuse P., Garcia E., Regina A., Debray M., Andreux J.P., et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 2005, 93:279-289.
25. van Buul J.D., Allingham M.J., Samson T., Meller J., Boulter E., Garcia-Mata R., et al. RhoG regulates endothelial apical cup assembly downstream from ICAM1 engagement and is involved in leukocyte trans-endothelial migration. J Cell Biol 2007, 178:1279-1293.
26. Bruck W., Sommermeier N., Bergmann M., Zettl U., Goebel H.H., Kretzschmar H.A., et al. Macrophages in multiple sclerosis. Immunobiology 1996, 195:588-600.
27. van der Valk P., De Groot C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000, 26:2-10.
28. Goralski K.B., Hartmann G., Piquette-Miller M., Renton K.W. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003, 139:35-48.
29. Tai L.M., Reddy P.S., Lopez-Ramirez M.A., Davies H.A., Male A.D., Loughlin A.J., et al. Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. Brain Res 2009.
30. Turowski P., Adamson P., Greenwood J. Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation. Cell Mol Neurobiol 2005, 25:153-170.
31. Abbott N.J., Khan E.U., Rollinson C.M., Reichel A., Janigro D., Dombrowski S.M., et al. Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found Symp 2002, 243:38-47.
32. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
33. Bauer B., Yang X., Hartz A.M., Olson E.R., Zhao R., Kalvass J.C., et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006, 70:1212-1219.
34. Rudick R.A., Cohen J.A., Weinstock-Guttman B., Kinkel R.P., Ransohoff R.M. Management of multiple sclerosis. N Engl J Med 1997, 337:1604-1611.
35. Cucullo L., Hallene K., Dini G., Dal T.R., Janigro D. Glycerophosphoinositol and dexamethasone improve transendothelial electrical resistance in an in vitro study of the blood-brain barrier. Brain Res 2004, 997:147-151.
36. Roberts D.J., Goralski K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008, 4:1245-1264.
37. Nwaozuzu O.M., Sellers L.A., Barrand M.A. Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem 2003, 87:1043-1051.
38. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001, 107:247-254.
39. van Loo G., De L.R., Schmidt H., Huth M., Mildner A., Schmidt-Supprian M., et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol 2006, 7:954-961.
40. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
41. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.